This is a single-center observational study, whose primary objective is to describe the immune response to Oropouche Virus (OROV) during the study period and the duration of viral RNA shedding, only for sequential samples, by RT-PCR in different matrices.
Eligibility
Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
* patients resulted positive to the RT-PCR for OROV;
* informed consent to the participation to the study and to personal data's treatment and/or donation of residual samples to Tropika Biobank;
* patients ≥ 18 years old.
Exclusion Criteria
• lack of signed informed consent.
Primary outcome measure(s)
Anti-OROV serum antibody response — Baseline, 7 days post symptoms onset (DPSO), 14 days DPSO, 21 days DPSO, 28days DPSO, 60days DPSO, 90days DPSO Results of the anti-OROV serum antibody response along the study period:
* IgM (titer, reciprocal of dilution);
* IgG (titer, reciprocal of dilution).
OROV viral RNA shedding in different matrices — Baseline, 7 days post symptoms onset (DPSO), 14 days DPSO, 21 days DPSO, 28days DPSO, 60days DPSO, 90days DPSO Results of OROV viral RNA presence in different matrice along the study period:
RT-PCR Ct and RNA copies/mL in different matrices: urine, whole blood, serum, vaginal swab or seminal fluid, CSF and amniotic fluid if available.
Trial sites (1)
Facility
City
Region
Status
IRCCS Sacro Cuore Don Calabria
Negrar
VR
Recruiting
More IRCCS Sacro Cuore Don Calabria di Negrar trials in Italy
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.